X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Applied Biology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
Kintor Pharmaceutical's Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide's treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
China National Medical Products Administration (NMPA) announced on February 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
